Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Gyre Therapeutics (GYRE)

Gyre Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GYRE
DateTimeSourceHeadlineSymbolCompany
27/11/202421:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
27/11/202421:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GYREGyre Therapeutics Inc
25/11/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GYREGyre Therapeutics Inc
14/11/202421:39Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GYREGyre Therapeutics Inc
13/11/202411:00GlobeNewswire Inc.Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
22/10/202420:05GlobeNewswire Inc.Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver FibrosisNASDAQ:GYREGyre Therapeutics Inc
01/10/202420:05GlobeNewswire Inc.Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor ConferenceNASDAQ:GYREGyre Therapeutics Inc
06/09/202412:31Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GYREGyre Therapeutics Inc
06/09/202412:15Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GYREGyre Therapeutics Inc
04/09/202420:05GlobeNewswire Inc.Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:GYREGyre Therapeutics Inc
13/08/202410:00GlobeNewswire Inc.Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
09/08/202411:00GlobeNewswire Inc.Gyre Therapeutics to Present at Sidoti Virtual Investor ConferenceNASDAQ:GYREGyre Therapeutics Inc
08/08/202420:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
08/08/202420:05GlobeNewswire Inc.Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of DirectorsNASDAQ:GYREGyre Therapeutics Inc
02/07/202420:05GlobeNewswire Inc.Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaNASDAQ:GYREGyre Therapeutics Inc
18/06/202420:05GlobeNewswire Inc.Gyre Therapeutics Announces Publication in Journal of Gastroenterology and HepatologyNASDAQ:GYREGyre Therapeutics Inc
17/06/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
30/05/202420:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GYREGyre Therapeutics Inc
30/05/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
30/05/202420:05GlobeNewswire Inc.Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial HypertensionNASDAQ:GYREGyre Therapeutics Inc
30/05/202420:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GYREGyre Therapeutics Inc
28/05/202420:05GlobeNewswire Inc.Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® IndexesNASDAQ:GYREGyre Therapeutics Inc
13/05/202420:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GYREGyre Therapeutics Inc
09/05/202420:10GlobeNewswire Inc.Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
09/05/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
08/05/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
26/03/202410:00GlobeNewswire Inc.Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
21/03/202411:00GlobeNewswire Inc.Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. NussbaumNASDAQ:GYREGyre Therapeutics Inc
15/12/202314:04PR Newswire (US)Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B FundingNASDAQ:GYREGyre Therapeutics Inc
13/11/202312:00GlobeNewswire Inc.Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver MeetingNASDAQ:GYREGyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GYRE